NEW YORK: Pfizer, the US pharmaceutical behemoth, announced on Thursday the completion of its acquisition of the cancer-focused biotechnology company Seagan Inc, reported dpa news.Pfizer completed the acquisition for US$229 per share, for a total enterprise value of approximately US$43 billion.Pfizer said Seagan’s four approved cancer therapies will bolster its oncology portfolio, which now includes over 25 approved medicines and biosimilars.As previously disclosed, to address US Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of the immuno-oncology drug Bavencio in the US to the American Association for Cancer Research (AACR).-Be
Hence then, the article about pfizer closes deal to acquire cancer focused seagen for us 43 billion was published today ( ) and is available onDaily Sun ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Pfizer closes deal to acquire cancer-focused Seagen for US$43 billion )